Share Price:

APNASPENAspen Pharmacare Hldgs22013-487 (-2.16%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen building momentum with revenue up 10% to R21,1 billion

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion

Aspen concludes two significant agreements with Sandoz for China and Europe

Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded two interdependent agreements with Sandoz AG (“Sandoz”) concerning the acquisition of Sandoz’s Chinese business and the disposal to Sandoz of four anaesthetic products in… Continue reading Aspen concludes two significant agreements with Sandoz for China and Europe

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.